Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis
Archives of Biochemistry and Biophysics · 2024-12 · 762 · 110193
DOI: 10.1016/j.abb.2024.110193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2024-12. Verfasst von Dian Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Ferroptosis, Apoptosis, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Scientific Research Fund of Liaoning Provincial Education Department, Department of Education of Liaoning Province.
Abstract (Originalsprache)
Ovarian cancer is a frequently observed type of gynaecologic malignancy generally associated with poor prognosis around the world. Ubiquitin-specific proteases (USPs) form the largest subfamily of deubiquitylating enzymes and have emerged as potential therapeutic targets against human cancers. Through a systematic analysis of the prognostic significance of USP expression, USP2 was found to be inversely correlated with patient survival in ovarian cancer. Accordingly, we investigated the effects of pharmacological inhibition of USP2 on ovarian cancer by exploiting its small molecule inhibitor ML364. Our findings show that ML364 effectively hindered ovarian cancer growth and migration using a series of in vitro assays. In addition to apoptosis induction, ML364 also sensitized ovarian cancer cells to ferroptosis. Mechanistically, ML364 treatment resulted in cyclin D1 downregulation, increased poly (ADP-ribose) polymerase (PARP) cleavage, and elevated ROS levels in ovarian cancer cells. Collectively, our findings suggest USP2 as a potential therapeutic target in ovarian cancer, and hence, its pharmacological inhibition warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China; Department of Gynecology, Zhongshan Hospital of Dalian University, Dalian, China.
- Department of Radiation Oncology, The Second Affiliated Hospital, Dalian Medical University, China. Electronic address: maruilan2000@163.com.
- Department of Oncology, The Second Affiliated Hospital, Dalian Medical University, China. Electronic address: liufang_dy@sina.com.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. Electronic address: liusy@dmu.edu.cn.
Förderung
- China Postdoctoral Science Foundation
- Scientific Research Fund of Liaoning Provincial Education Department
- Department of Education of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Yang, D., Liu, X., Yang, Y., Long, Y., Nan, D., Shi, B., Wang, J., Yang, M., Cong, H., Xing, L., Zhou, F., Yuan, Q., Ta, N., Zhang, Y., Ma, R., Liu, F., & Liu, S. (2024). Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis. Archives of Biochemistry and Biophysics, 762, 110193. https://doi.org/10.1016/j.abb.2024.110193
Vancouver
Yang D, Liu X, Yang Y, Long Y, Nan D, Shi B, et al. Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis. Archives of Biochemistry and Biophysics. 2024;762:110193. doi:10.1016/j.abb.2024.110193
BibTeX
@article{Yang2024,
author = {Yang, Dian and Liu, Xiuxiu and Yang, Yinghui and Long, Yu and Nan, Ding and Shi, Bo and Wang, Jinhao and Yang, Mei and Cong, Haotian and Xing, Lin and Zhou, Feixue and Yuan, Qianhui and Ta, Na and Zhang, Yingqiu and Ma, Ruilan and Liu, Fang and Liu, Shuyan},
title = {Pharmacological USP2 targeting suppresses ovarian cancer growth by potentiating apoptosis and ferroptosis},
journal = {Archives of Biochemistry and Biophysics},
year = {2024},
volume = {762},
pages = {110193},
doi = {10.1016/j.abb.2024.110193}
}
EUVIMED